Učitavanje...
EGFR-TKIs resistance via EGFR-independent signaling pathways
Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer. Unfortunately, the majority of these patients ultimately develop to the acquired resistance after a period of treatm...
Spremljeno u:
| Izdano u: | Mol Cancer |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5817859/ https://ncbi.nlm.nih.gov/pubmed/29455669 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-018-0793-1 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|